GPX3 promoter hypermethylation and downregulation were detected in prostate cancer [15]; endometrial adenocarcinoma [16]; cervical, thyroid, and lung cancer [17]; head and neck carcinoma [14]; gastric cancer [18]; and multiple myeloma [19]. Here, GPX3 is linked to prostate cancer.